GLWL 01

Drug Profile

GLWL 01

Alternative Names: GLWL-01

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer GLWL Research
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 14 Feb 2017 GLWL Research terminates a phase I trial in Type-2 diabetes mellitus in USA due to insufficient efficacy for this indication (NCT02377362)
  • 13 Jan 2017 GLWL Research suspends participant recruitment in a phase I trial in Type-2 diabetes mellitus in USA (NCT02377362)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top